Online inquiry

IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6486MR)

This product GTTS-WQ6486MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6486MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10896MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ5180MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ11128MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ1750MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ2162MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ1136MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ11854MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ15237MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TAK-079
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW